Antibody methods for selectively inhibiting VEGF
US6524583B1 · kind B1 · utility
116Cited by
41References
40Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2000 |
| Grant date | Feb 25, 2003 |
| Priority date | — |
| Expiry date | Apr 28, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.